Tele: 561.316.3330
Breaking Medical Device News

Saturday, October 16, 2021
HomeSafe Label SystemCodonics ® Becomes Exclusive Distributor of Pharmacolog AB WasteLog Technology in North...

Codonics ® Becomes Exclusive Distributor of Pharmacolog AB WasteLog Technology in North America


Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets –

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts –

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.

March 3, 2021

Codonics has signed an agreement with Pharmacolog AB, specialized in developing systems and solutions for more effective and safer use of intravenous drugs, making Codonics the exclusive U.S. distributor of Pharmacolog’s WasteLog technology.

When integrated with Codonics Safe Label System®, the combined solution provides the most accurate end-to-end diversion control system with a quick and efficient workflow. Together, these technologies will play a critical role in addressing the challenges hospitals face in preventing the diversion of controlled substances globally.

The stakes for solving, or at minimum mitigating, diversion are high because of risks to those that divert as well as to the entire healthcare system. Complicating an already complex problem are the challenges  COVID-19 has introduced. Hospitals are now facing added difficulties caring for COVID-19 patients due to the increased amounts of controlled substances being administered combined with the rapid adjustments to the workflow that could contribute to the breakdowns in the normal checks against diversion.

Although Safe Label System and WasteLog™ can be purchased and implemented independently, the integration combines electronic safety checks during medication preparation and administration with better management of the medical waste workflow for a novel approach to drug diversion.

In the operating room or wherever medications are prepared, Codonics Safe Label System reads the barcode from parenteral vials and ampoules, provides visual and audible confirmation to ensure the drug in hand, then prints a TJC-compliant label that carries the NDC data from that barcode to the prepared syringe.

The syringe barcode can be scanned prior to administration for electronic documentation of the medication and concentration including the exact NDC for accurate charge capture and 340B documentation into AIMS/EMR, such as Epic.

In Pharmacy or anywhere returns occur, Safe Label System syringes can be scanned enabling WasteLog™ to electronically identify the drug and concentration. Simply injecting a small volume from the syringe (0.3-0.5 mL) into a cuvette enables WasteLog™ to verify the contents. In <3 seconds, WasteLog™ presents a very robust and highly accurate result via the integrated screen. Once the drug is assayed, key data and diversion insight is quickly available for in-depth analysis such as trend analysis, report generators and data filters.

“We have been focused on establishing strategic partnerships with major international players and are very pleased to have entered into this partnership agreement with Codonics,” said Mats Högberg, CEO, Pharmacolog.  “Our partnership provides Pharmacolog with access to Codonics’ existing and growing market and enables us to increase our footprint into this growing healthcare space. The combined solution assures the highest level of safety and compliance will be achieved.”



AMRA Medical’s Whole-body MRI Analysis Used in FSHD Clinical Trial Research Network Study for Biomarker Development

To date, the MOVE study has used functional tests as primary outcomes, but recent studies have shown the promise of MRI for FSHD.

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA

“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons.  We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy